## PARADIGM BIOPHARMACEUTICALS LIMITED



ASX RELEASE

7 April 2020

## PARADIGM TO HOST INVESTOR CALL TO DISCUSS US FDA REGULATORY PATHWAY, LATEST SAS REAL WORLD DATA AND CAPITAL RAISING PROCESS

**Melbourne 7 April 2020, Paradigm Biopharmaceuticals Ltd (ASX: PAR):** Paradigm is pleased to announce that it will **host a conference call at 8:30am (AEST) Wednesday 8<sup>th</sup> April** to discuss the recent minutes provided by the US FDA and guidance over the requirements for the Phase 3 clinical trial design and NDA submission. The company will also discuss the recent SAS data on 34 patients who have been treated using the Phase 3 material and measured with the same endpoints that will be used in the Phase 3 clinical trials.

Investors are encouraged to send through questions by 8:00pm (AEST) Tuesday 7<sup>th</sup> April, with the company collating questions sent and will endeavour to answer the most frequently asked.

Questions are to be submitted to investorrelations@paradigmbiopharma.com

## **Teleconference Details**

You are invited to participate in a conference call held by Paradigm Biopharmaceuticals Limited CEO, Paul Rennie.

The call is scheduled for 8:30am (AEST) Wednesday 8<sup>th</sup> April. (US PST 3pm / EST 6 pm on Tueday 7<sup>th</sup>; Hong Kong 6:30am).

## **Dial-in Details**

*Register for the call at the following link: <u>https://s1.c-conf.com/diamondpass/10005685-</u> <u>invite.html</u>* 

You will then be provided with the dial in number, the Passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.

To join the conference, simply dial the number in the calendar invite and enter the passcode followed by your PIN, and you will join the conference instantly.

FOR FURTHER INFORMATION PLEASE CONTACT: Simon White Director of Investor Relations Tel: +61 404 216 467 **Paradigm Biopharmaceuticals Ltd** ABN: 94 169 346 963 Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA Email : investorrelations@paradigmbiopharma.com